| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 85.74% | 81.30% | 95.86% |
| Operating Margin | -18.14% | -19.59% | -160.15% | 25.22% | 8.49% | -77.30% | -84.72% |
| EBITDA Margin | 7.13% | 1.08% | -141.59% | 46.60% | 34.68% | -52.43% | -39.86% |
| Net Margin | -25.59% | -17.27% | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% |
| Current Ratio | 1.70 | 1.77 | 1.83 | 1.39 | 0.77 | 0.71 | 0.56 |
| Quick Ratio | 1.51 | 1.43 | 1.43 | 1.24 | 0.71 | 0.62 | 0.54 |
| Debt / Equity | 0.42 | 0.32 | 0.28 | 0.30 | 0.72 | 1.51 | 6.06 |
| ROE | -32.33% | -17.82% | -240.53% | 48.57% | -1.25% | -50.70% | -374.76% |
| ROA | -11.38% | -7.58% | -115.89% | 26.49% | -0.39% | -9.28% | -41.20% |
| Asset Turnover | 0.44 | 0.44 | 0.53 | 0.38 | 0.34 | 0.35 | 0.44 |
| Book Value / Share | 14.67 | 1.27 | 1.94 | 4.13 | 2.37 | 0.53 | 0.82 |
Assertio Holdings Inc. is a leading commercial pharmaceutical company that brings differentiated branded prescription products to patients across key therapeutic areas. It maintains a robust portfolio focused on neurology, inflammation, pain management, oncology, and hospital products, including medications such as INDOCIN for treating rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis, and acute painful shoulder; Sympazan, a benzodiazepine for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome; Otrexup, SPRIX, CAMBIA, and Zipsor; as well as Rolvedon in oncology following strategic business development. The company specializes in acquiring, licensing, and optimizing commercial-stage assets through an acquisition-driven model, emphasizing targeted marketing and lifecycle management to serve patients primarily in the United States. Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings Inc. plays a vital role in the specialty pharmaceuticals sector by providing established, high-margin products in neuroscience, immunology, and oncology.